AI Article Synopsis
- The SARS-CoV-2 B.1.617 variant was discovered in Maharashtra, India, in late 2020, raising concerns about its ability to evade antibodies.
- Key mutations L452R and E484Q were studied to see if they together would increase this evasion effect.
- The findings indicate that while these mutations do reduce the vaccine's effectiveness slightly, they do not work together to create a stronger resistance to the vaccines, behaving similarly to their effects when present individually.
Article Abstract
The SARS-CoV-2 B.1.617 variant emerged in the Indian state of Maharashtra in late 2020. There have been fears that 2 key mutations seen in the receptor-binding domain, L452R and E484Q, would have additive effects on evasion of neutralizing antibodies. We report that spike bearing L452R and E484Q confers modestly reduced sensitivity to BNT162b2 mRNA vaccine-elicited antibodies following either first or second dose. The effect is similar in magnitude to the loss of sensitivity conferred by L452R or E484Q alone. These data demonstrate reduced sensitivity to vaccine-elicited neutralizing antibodies by L452R and E484Q but lack of synergistic loss of sensitivity.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420622 | PMC |
| http://dx.doi.org/10.1093/infdis/jiab368 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!